Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Cellectis    ALCLS   FR0010425595

CELLECTIS

(ALCLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cellectis : An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery

share with twitter share with LinkedIn share with facebook
share via e-mail
01/07/2020 | 04:59am EDT

* Cellectis and World Experts Review New Avenue of Allogeneic CAR T-cells, Optimization and Promises in Oncology

New York (N.Y.) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the publication of a review in Nature Reviews Drug Discovery by Prof. Stephane Depil1*, Dr. Philippe Duchateau2, Prof. Stephan Grupp3, Prof. Ghulam Mufti4 and Dr. Laurent Poirot2. The authors review the opportunities and challenges presented by universal allogeneic CAR T-cell therapies.

One of the most promising approaches in cancer treatment is chimeric antigen receptor (CAR) T-cell therapy, in which part of the body's own immunological defendors, T-cells, are redirected against cancerous cells after being engineered to express CARs. Since their initial development in the early 90s, CAR T-cells have evolved through several generations. The use of autologous (patient-derived) CAR T-cells has proven to be successful in treating people with certain blood cancers such as B-cell malignancies. However, autologous CAR T-cell therapy is not suitable for all patients, and it often requires a long and expensive manufacturing process since each treatment must be made individually for each patient.

Cellectis was the first company to develop and test an allogeneic CAR T-cell therapy in patients, where T-cells are derived from healthy donors. This gives rise to off-the-shelf product candidates which aim to be suitable for many patients as opposed to only a single person.

"We realized early on that refined gene-editing techniques were what was needed to take an allogeneic approach to CAR T-cell therapy," said Dr. Laurent Poirot, VP, Immunology Division, Cellectis. "Despite the complexity of this approach, we decided to follow this route because we are confident that it can provide the most impact for a maximum number of people living with severe cancers. This comprehensive review underlines just how much this technology has evolved in very little time. It also gives us exciting areas to explore as we continue to improve our product candidates."

One of the major challenges in the allogeneic approach involves mitigating the risk of graft-versus-host-disease (GvHD) - a medical complication that can present itself in people that have received tissues or cells from another person. The review examines aspects of this challenge and helps weigh the pros and cons associated with the different methods used to create allogeneic CAR T-cells. It also outlines some of the gene-editing work that Cellectis has done in this area along with complementary approaches being taken by others in the field, such as using cells other than conventional T-cells, also known as alpha beta T-cells.

"Our immune system, including our T-cells, is incredibly sophisticated. We know that T-cells can now be retasked to successfully fight cancer. There are amazing approaches to gene editing that are driving progress towards the most safe and efficacious versions of allogeneic products. It is exciting to see these approaches applied to 'off the shelf' CAR T-cell products," said Prof. Stephan Grupp, Chief of Cell Therapy and Transplant Section at the Children's Hospital of Philadelphia, Professor of Pediatrics at the Perelman School of Medicine, and a member of Cellectis'Clinical Advisory Board. "I'm looking forward to seeing emerging clinical data as well as even newer approaches, as Cellectis' expertise in gene-editing technology continues to transform CAR-T".

Off-the-shelf' allogeneic CAR T cells: new development and current challenges

Stephane Depil1*, Philippe Duchateau2, Stephan Grupp3, Ghulam Mufti4, Laurent Poirot2

1Formerly Cellectis, now Centre Leon Berard and Centre de Recherche en Cancerologie de Lyon, 28 rue Laennec, 69008 Lyon, France

2Cellectis, 8 rue de la Croix Jarry, 75013, Paris, France

3Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, 3401 Civic Center Blvd Philadelphia, PA 10104, USA

4King's College London and King's College Hospital, Denmark Hill, London, SE5 9RS, United Kingdom

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CELLECTIS
03/26CALYXT, INC. : Financial Statements and Exhibits (form 8-K)
AQ
03/11CELLECTIS : US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to C..
AQ
03/10CELLECTIS S A : US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted ..
BU
03/05CALYXT, INC. : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
03/04CELLECTIS : Provides Business Update and Reports 4th Quarter and Full Year 2019 ..
BU
03/04CELLECTIS : and Servier Execute the Amendment Confirming the Expansion of Their ..
BU
02/25CELLECTIS TO HOLD FOURTH QUARTER AND : 30 am est
BU
02/19CELLECTIS : and Servier Expand Collaboration on UCART19 Products; Cellectis : gr..
AQ
02/18CELLECTIS : and Servier Expand Collaboration on UCART19 Products
BU
02/05CALYXT, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Financials (EUR)
Sales 2020 36,7 M
EBIT 2020 -130 M
Net income 2020 -119 M
Finance 2020 181 M
Yield 2020 -
P/E ratio 2020 -2,95x
P/E ratio 2021 -3,30x
EV / Sales2020 4,34x
EV / Sales2021 3,04x
Capitalization 340 M
Chart CELLECTIS
Duration : Period :
Cellectis Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 25,05  €
Last Close Price 8,00  €
Spread / Highest target 219%
Spread / Average Target 213%
Spread / Lowest Target 208%
EPS Revisions
Managers
NameTitle
André Choulika Chairman & Chief Executive Officer
Elsy Boglioli Chief Operating Officer
Eric Dutang Chief Financial Officer
Philippe Duchateau Chief Scientific Officer
Stephane Depil Chief Medical Officer, EVP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CELLECTIS-48.98%377
LONZA GROUP11.21%29 660
IQVIA HOLDINGS INC.-30.66%20 658
CELLTRION, INC.3.08%20 147
SEATTLE GENETICS, INC.-4.37%18 823
INCYTE CORPORATION-16.34%14 949